Evommune, Inc.

EVMN NYSE SEC CIK 2044725
Follow Evommune Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0 −100% vs same quarter last year
Net income −$30.9M −147.5% vs same quarter last year
EPS, diluted −$0.85 +89.5% vs same quarter last year
Operating cash flow −$25.9M −168.6% vs same quarter last year
Revenue by quarter
$0
$3M
$0
$10M
$0
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing